O-β-D-mannopyranosyl-(1->4)-D-mannopyranose | 15548-43-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: O-β-D-mannopyranosyl-(1->4)-D-mannopyranose
• 英文别名: mannobiose；4-O-β-D-mannopyranosyl-D-mannose；4-O-β-D-mannopyranosyl-D-mannopyranose；4-O-beta-D-Mannopyranosyl-D-mannopyranose；(2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
• CAS: 15548-43-3
• 化学式: C₁₂H₂₂O₁₁
• 分子量: 342.3
• InChiKey: GUBGYTABKSRVRQ-KWCWEWCRSA-N

物化性质

• 熔点：
  202-203 °C
• 沸点：
  667.9±55.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  190
• 氢给体数：
  8
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  O-β-D-mannopyranosyl-(1->4)-D-mannopyranose 生成 2,3,6-tri-O-methyl-D-mannose 、 2,3,4,6-tetra-O-methyl-D-mannose
  参考文献：
  名称：

  决明子的非离子种子胶

  摘要：

  摘要用冷酸水从决明子种子中提取多糖，纯化后制成摩尔比为4：7的d-半乳糖和d-甘露糖的水溶性产物。酸催化的裂解，高碘酸盐氧化，甲基化和酶水解表明，种子胶具有由β-d-（1→4）连接的甘露吡喃糖基单元的线性链组成的支链结构，其中一些在O-处被取代。 6由两个α-d-（1→6）吡喃半乳糖苷单元相互糖苷键连接。半乳甘露聚糖的甲基化分析提供了2,3,4-三-和2,3,4,6-四-O-甲基半乳糖，以及2,3-二-和2,3,6-三-O-甲基甘露糖，以2：2：2：5的摩尔比。甲基化和高碘酸氧化研究均显示约36.4％的端基。这些结果的意义，

  DOI：

  10.1016/0008-6215(84)85011-9
• 作为产物：
  描述：

  benzyl 2,3-di-O-benzyl-6-acetyl-4-O-(2,3-di-O-benzyl-6-O-acetyl-β-D-mannopyranosyi)-β-D-mannopyranoside 在 potassium carbonate 、 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以58%的产率得到O-β-D-mannopyranosyl-(1->4)-D-mannopyranose
  参考文献：
  名称：

  一种寡糖类化合物在神经保护方面的应用

  摘要：

  本发明涉及式（I）所示的寡糖类化合物(包括甘露糖寡糖，纤维糖寡糖和麦芽糖寡糖)及其立体异构体、互变异构体、溶剂合物或前药在神经保护方面的应用：式（I）中，n表示0或1-5的整数。

  公开号：

  CN103340881B

文献信息

• [EN] BINDING-SITE MODIFIED LECTINS AND USES THEREOF<br/>[FR] LECTINES DE SITE DE LIAISON MODIFIÉES ET USAGE CORRESPONDANT
  申请人：SMARTCELLS INC

  公开号：WO2010088261A1

  公开（公告）日：2010-08-05

  In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.

  在一个方面，该公开提供了包括多价凝集素的交联材料，其中该多价凝集素具有至少两个葡萄糖结合位点，其中该凝集素包括至少一个与亲和配体共价连接的亲和配体，该亲和配体能够与至少一个所述结合位点中的葡萄糖竞争结合；以及包括绑定到共轭框架的两个或更多个独立亲和配体的共轭物，其中这两个或更多个亲和配体与葡萄糖在所述结合位点上与凝集素竞争结合，其中由于不同共轭物上的凝集素和亲和配体之间的非共价相互作用，共轭物在材料内交联。这些材料旨在根据所需葡萄糖浓度释放共轭物的量。根据最终应用，在各种实施例中，共轭物还可以包括药物和/或可检测标记。
• POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
  申请人：Wu Nian

  公开号：US20150157721A1

  公开（公告）日：2015-06-11

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架，以及三个或四个附加的功能基团：一个或两个疏水化合物，包括固醇或“脂溶性”维生素，一个或两个亲水性聚合物，以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物，其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体，一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间，以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
• [EN] DESFERRITHIOCIN ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE LA DESFERRITHIOCINE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2015077655A1

  公开（公告）日：2015-05-28

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁过载与病理条件相关，如氧化应激、输血性铁过载、地中海贫血、原发性血色病、继发性血色病、糖尿病、肝病、心脏病、癌症、放射损伤、神经或神经退行性疾病、弗里德雷希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激综合征和再灌注损伤。本发明提供使用式（A）和（J）的去铁胱醇类似物的方法和药物组合物，用于治疗和/或预防这些病理条件、金属（如铁、铝、镧系元素或锕系元素（如铀））过载症状和传染病（如疟疾）。
• [EN] GLUCOSE-RESPONSIVE INSULIN CONJUGATES<br/>[FR] CONJUGUÉS D'INSULINE SENSIBLES AU GLUCOSE
  申请人：MERCK SHARP & DOHME

  公开号：WO2021021535A1

  公开（公告）日：2021-02-04

  Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.

  提供含有一种或多种三糖的对葡萄糖反应的胰岛素结合物。这样的胰岛素结合物可能显示出对葡萄糖或α-甲基甘露糖等糖类的全身浓度有响应的药代动力学（PK）和/或药效学（PD）特征，即使在没有外源性多价糖类结合分子的存在下，给予需要它的受试者。
• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。